Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products include Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has completed Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIa clinical tri...
1550 East Gude Drive
Rockville, MD 20850
Founded in 2005
Supernus Pharmaceuticals, Inc. Announces Resignation of Jones W. Bryan as Vice President of Business Development
Mar 27 15
On March 26, 2015, Jones W. Bryan, Ph.D., Vice President of Business Development, resigned from Supernus Pharmaceuticals, Inc., effective April 9, 2015, to pursue other interests.
Supernus Pharmaceuticals, Inc. Appoints Georges Gemayel to the Board of Directors
Mar 23 15
Supernus Pharmaceuticals, Inc. announced that Georges Gemayel, Ph.D., an executive with extensive experience in the pharmaceutical industry, will join the company's board of directors. Dr. Gemayel has over 25 years of experience in the pharmaceutical industry, including management and executive positions in the U.S., Europe and the Middle East. Dr. Gemayel currently serves on the board of directors of Raptor Pharmaceuticals, a publicly-traded company, and is the chairman of the boards of OxThera, EpiTherapeutics and Orphazyme ApS. From 2008 to 2009, Dr. Gemayel was president and chief executive officer of Altus Pharmaceuticals, a publicly-traded pharmaceutical company. From 2003 to 2008, he was executive vice president at Genzyme Corporation where he was responsible for the company's global therapeutics, transplant, renal and biosurgery businesses.
Supernus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year 2015
Mar 10 15
Supernus Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $30,801,000 against $10,334,000 a year ago. Operating income was $4,729,000 against operating loss of $11,357,000 a year ago. Net income was $4,354,000 or $0.10 per basic and diluted share against net loss of $22,406,000 or $0.65 per basic and diluted share a year ago. Non-GAAP net income for the fourth quarter of 2014 was $3.7 million, compared to the non-GAAP net loss for the fourth quarter of 2013 of $13.4 million. This year over year improvement in net income is driven by increased revenue associated with higher prescription volumes for Oxtellar XR and Trokendi XR, partially offset by an increase in marketing and research expenditures. Cash flow positive for the fourth quarter, $5.9 million.
For the year, the company reported total revenue of $122,045,000 against $12,019,000 a year ago. Operating income was $24,230,000 against operating loss of $61,920,000 a year ago. Net income was $19,871,000 or $0.32 per diluted share against net loss of $92,273,000 or $2.90 per diluted share a year ago. Non-GAAP net loss for full year 2014 was $10.3 million, compared to the non-GAAP net loss for full year 2013 of $69.4 million. This improvement is driven primarily by increased revenue associated with higher prescription volumes from Oxtellar XR and Trokendi XR, partially offset by expenses associated with the expansion of sales force, an increase in marketing expenditures associated with that sales force expansion, and an increase in research and development expenses associated with the development of both of product candidates, SPN-810 and SPN-812. Cash flow for full year 2014 was approximately $3.2 million, including $30.0 million in revenue from royalty agreement, which was offset partially by losses from on-going operations
For full year 2015, the company estimates that product revenue will grow by approximately 50%, ranging from $130 million to $140 million, with operating income ranging from $6 million to $10 million.